JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?…
JNJ·Healthcare·Dividend Aristocrats
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?…
CLOV·Healthcare·Meme Stocks
Did CMS just hand Clover Health the kind of rating upgrade that can change its growth story overnight? Maik Kemper…
NVO·Healthcare·Pharma
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s…
NVO·Healthcare·Pharma
Can the Novo Nordisk Wegovy Trial strengthen its obesity lead just as Wall Street starts pricing in the next GLP-1…
MDT·Healthcare·Dividend Aristocrats
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike? Maik Kemper Editor in…
LLY·Healthcare·Pharma
Can Eli Lilly LillyDirect turn obesity drugs into a full-service care platform that rivals cannot easily copy? Maik Kemper Editor…
UNH·Healthcare
Can a fresh Wall Street buy call finally reset the narrative around UnitedHealth after months of Medicare pressure? Maik Kemper…
NVO·Healthcare·Pharma
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper…
LLY·Healthcare·Pharma
Can restored CVS access turn Eli Lilly Zepbound Coverage into the next big advantage in the obesity drug war? Maik…
LLY·Healthcare·Pharma
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines? Maik Kemper Editor in…